The FDA decision on Daré Bioscience Inc’s (DARE) DARE-BV1, proposed for the treatment of bacterial vaginosis, is scheduled for December 7. DARE-BV1 is a thermosetting vaginal gel formulated with antibiotic Clindamycin phosphate 2% and in clinical trials, it has demonstrated a cure rate of 70% to 80%.Bacterial vaginosis is the most common vaginal infection in women of ages 15 to 44, and it affects about 21 million women in the United States. Studies suggest that bacterial vaginosis is linked to premature deliveries and low birth weight babies, increases susceptibility to sexually transmitted infections like HIV, herpes simplex virus, chlamydia, gonorrhea, and may cause pelvic inflammatory disease. Antibiotics are the mainstay of therapy for bacterial vaginosis and the clinical cure rates of the current approved medicines are in the range of 37% to 68%.DARE closed Friday’s trading at $1.79, up 1.13%.